Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 220 of 5804
-
Can two drugs together fight Hard-to-Treat bone and Soft-Tissue cancers?
Disease control Recruiting nowThis is a multicenter, open-label, Phase 1/2 study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of domatinostat in combination with sirolimus in adolescents and adults with relapsed or refractory sarcoma and osteosarcoma.
Phase: PHASE1, PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New monthly shot could ease Sjögren's dry mouth
Symptom relief Recruiting nowThe purpose of this study is to demonstrate the efficacy and safety of ianalumab (VAY736) 300 mg administered subcutaneously (s.c.) monthly for 52 weeks in adult participants with Sjögren's disease who have high symptom burden.
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Symptom relief
Last updated Jul 11, 2026 00:00 UTC
-
Gene therapy hope for kids with rare citrate disorder
Disease control Recruiting nowPhase 1/2, open-label study to assess the efficacy and safety of a single lumbar intrathecal administration of TSHA-105 in individuals with SLC13A5 Citrate Transporter Disorder
Phase: PHASE1, PHASE2 • Sponsor: TESS Research Foundation • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Text messages could be a lifeline for teens at risk of suicide
Symptom relief Not yet recruitingThe goal of this pilot clinical trial is to learn if Caring Contacts (brief, hopeful, supportive text messages) can be delivered to adolescents with suicidal thoughts or behaviors after discharge from the emergency department, and to understand if adolescents find it acceptable t…
Phase: NA • Sponsor: Ann & Robert H Lurie Children's Hospital of Chicago • Aim: Symptom relief
Last updated Jul 12, 2026 00:00 UTC
-
AI could spot hidden stroke type that often worsens quickly
Diagnosis Recruiting nowBranch atheromatous disease (BAD)-related stroke is an important subtype of acute ischemic stroke involving penetrating arteries and is associated with early neurological deterioration. Early recognition and standardized diagnosis remain challenging in routine clinical practice b…
Sponsor: Peking Union Medical College Hospital • Aim: Diagnosis
Last updated Jul 11, 2026 00:00 UTC
-
New mRNA vaccine aims to shield against RSV
⭐️ VACCINE ⭐️ Not yet recruitingA Phase 1 Study to Evaluate the Safety, Reactogenicity and Immunogenicity of YKYY025 Injection
Phase: PHASE1 • Sponsor: Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd. • Aim: ⭐️ VACCINE ⭐️
Last updated Jul 12, 2026 00:00 UTC
-
Could a simple spray shield cancer patients from radiation burns?
Symptom relief Not yet recruitingTo evaluate the efficacy and safety of superoxide dismutase skin spray for the reducing the acute radiation dermatitis in patients with head and neck malignancies undergoing radiotherapy.
Phase: PHASE2 • Sponsor: West China Hospital • Aim: Symptom relief
Last updated Jul 17, 2026 00:00 UTC
-
Could a tiny nerve implant silence sleep apnea without a mask?
Disease control Not yet recruitingThe objective of this study is to evaluate the safety and preliminary effectiveness of an implantable hypoglossal nerve stimulation system for moderate-to-severe obstructive sleep apnea (OSA).
Phase: NA • Sponsor: Beijing Pins Medical Co., Ltd • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Can a common arthritis drug stop Parkinson's before it starts?
Prevention Recruiting nowThis is a phase 2 study to assess the ability of adalimumab as compared to placebo to reduce or prevent progression of synuclein-related neurodegeneration in persons with idiopathic REM Sleep Behavior Disorder (RBD). The Primary Endpoint will be change from baseline in expression…
Phase: PHASE2 • Sponsor: Yale University • Aim: Prevention
Last updated Jul 25, 2026 00:00 UTC
-
Stroke showdown: which clot removal method saves more brain?
Disease control Not yet recruitingThis is a multicenter, open-label, blinded-endpoint, randomized controlled trial comparing super large bore catheter aspiration versus stent retriever thrombectomy as the first-line technique for anterior circulation large vessel occlusion in acute ischemic stroke. Eligible patie…
Phase: NA • Sponsor: Shanghai Jiao Tong University Affiliated Sixth People's Hospital • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New hope for pancreatic cancer: combo therapy enters phase 2 trial
Disease control Not yet recruitingPhase II, open label, randomized multicenter study to evaluate efficacy and safety of study treatment in previously untreated patients with advanced pancreatic cancer. Patients will receive study treatment for a maximum of 24 months or until progression disease or until unaccepta…
Phase: PHASE2 • Sponsor: Nelum Corp • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New hope for lymphoma: immune booster plus chemotherapy trial launches
Disease control Not yet recruitingA Phase II, open-label, two-arm, multicenter study evaluating the combination of epcoritamab with R-CHOP chemotherapy in patients with newly diagnosed, aggressive B-cell non-Hodgkin lymphoma.
Phase: PHASE2 • Sponsor: Mwanasha Merrill, MD • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Targeted radiation after lung cancer surgery aims to stop return
Disease control Recruiting nowThis phase II trial compares the effect of intensity-modulated post-operative radiation therapy (I²-PORT) followed by standard of care therapy (chemotherapy or immunotherapy) to standard of care therapy alone in treating patients with non-small cell lung cancer (NSCLC) who have r…
Phase: PHASE2 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New combo therapy aims to shrink rectal tumors before surgery
Disease control Recruiting nowThe purpose of this study is to evaluate the safety and clinical activity of combining cemiplimab, cemiplimab/fianlimab, or cemiplimab/REGN7075 with capecitabine/oxaliplatin (CAPOX) for the neoadjuvant treatment of patients with microsatellite stable (MSS) locally advanced rectal…
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Can early tumor response guide smarter cancer treatment?
Disease control Not yet recruitingEsophageal squamous cell carcinoma (ESCC) is a common and aggressive malignancy with poor prognosis, particularly in patients with locally advanced disease. Neoadjuvant chemoimmunotherapy has shown promising antitumor activity and may improve pathological response; however, a pro…
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Touch and tingle: Non-Drug therapies aim to tame chemo side effects
Symptom relief Recruiting nowHead and neck cancer (HNC) patients undergoing concurrent chemoradiotherapy (CCRT) frequently experience pain, xerostomia, fatigue, sleep disturbance, and other treatment-related toxicities that impair quality of life and treatment adherence, with incomplete relief from current s…
Phase: NA • Sponsor: Tzu Chi University • Aim: Symptom relief
Last updated Jul 26, 2026 00:00 UTC
-
Could a targeted antibody outdo steroids for a rare kidney disease?
Disease control Recruiting nowOBELIX-NEPHROSIS (NS) The goal of this clinical trial is to learn if obinutuzumab works to treat minimal change disease in adults. It will also learn about the safety of drug obinutuzumab. The main questions it aims to answer are: Is obinutuzumab non-inferior to glucocorticoids…
Phase: PHASE2 • Sponsor: Medical University Innsbruck • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
New drug targets two cancer proteins in advanced tumors
Disease control Not yet recruitingThis is a multicenter, open-label, multiple-dose, FIH Phase 1/2a trial. The Phase 1 portion uses Bayesian optimal interval (BOIN) design to escalate and determine the MTD and/or RP2D with potential backfill cohorts. The Phase 2a portion consists of dose optimization followed by c…
Phase: PHASE1, PHASE2 • Sponsor: VelaVigo Bio Inc • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Double-Drug attack: new combo aims to tackle tough lung cancer
Disease control Not yet recruitingThis is a single-arm clinical study evaluating the safety, tolerability, and preliminary efficacy of JS212 in combination with JS111 as first-line treatment in participants with epidermal growth factor receptor (EGFR)-mutant locally advanced or metastatic non-small cell lung canc…
Phase: NA • Sponsor: Huan Zhou • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Drug duo aims to tackle high blood pressure in obesity
Disease control Not yet recruitingThe EFFORT Study (Empagliflozin and Finerenone Combination in Obesity with Hypertension) is a 12-week, randomized, double-blind, placebo-controlled trial that aims to test whether combining empagliflozin (10 mg/day) with finerenone (10 mg/day, up-titrated to 20 mg after 4 weeks) …
Phase: NA • Sponsor: Heart Health Research Center • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC